/Investor DB

Astellas Venture Management LLC — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

Bicyclebicycletherapeutics.comin𝕏NASDAQ: BCYCMay 2024

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAhren Innovation CapitalCambridge Innovation CapitalDementia Discovery FundLongwood FundRidgeback CapitalSR One Capital Management+4 more

PhoreMost Limitedphoremost.comin𝕏Sep 2024

PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.

BiotechMedical DevicesCambridge, GB

Co-investorsAmadeus Capital PartnersCambridge Angels groupO2h VenturesUniversity of Cambridge EnterpriseAmadeus Capital SAParkwalk Advisors

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.